Loading, please wait...
| DOWNLOAD SCHEDULE » | DOWNLOAD EVAL TEMPLATE » | CE INSTRUCTIONS » | REQUEST PARKING » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Tuesday, October 15, 2019
St. Louis College of Pharmacy, Academic Research Building (ARB)
|
|
ARB 304
|
ARB 305
|
ARB 354
|
ARB 355
|
|
SESSION 1
1:00 – 1:45
|
Emily Shor, Pharm.D.
Op-TIME-izing the Initiation of Anticoagulation After Atrial Fibrillation-Associated Ischemic Stroke
|
Leslie Young, Pharm.D
Treating Urinary Tract Infections in the Face of Increasing Escherichia coli resistance
|
Kacee Verhovec, Pharm.D
The Safety and Efficacy of Electronic Cigarettes for Smoking Cessation
|
Annie Thorndyke, Pharm.D
Clear as Alphabet Soup? Review of the Treatment of Post-Transplant Lymphoproliferative Disease (PTLD)
|
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 2
1:55 – 2:40
|
Kalee Huddleston, Pharm.D
Treatment of VTE in cancer patients: Comparing LMWH vs. DOACs
|
Ezinwanne Emelue, Pharm.D
Treatment of carbapenem-resistant gram negative organism infections in pediatric patients
|
Kirsten Robles, Pharm.D
Alternatives to Opioids for Management of Postoperative Pain in Hip and Knee Arthroplasty in Opioid-Naive Patients
|
Caroline Powers, Pharm.D
Optimal Therapy for the Treatment of Mucormycosis
|
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
SESSION 3
2:50 – 3:40
|
|
Alexander Stumphauzer, Pharm.D
C-reactive Protein and Procalcitonin-guided Antibiotics in Patients with COPD Exacerbation
|
Lauren Jacobsmeyer, Pharm.D
Phenobarbital: A Phenomenal Drug in Alcohol Withdrawal Syndrome?
|
Michelle Ting, Pharm.D
Is Combination Therapy Needed for Salvage Therapy of MRSA Bacteremia?
|
Please join us for our first session of the 2019-2020 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. Alls essions will be held in the classrooms in the Academic & Research Building (ARB) on the third floor.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 2.25 contact hours. Participants must sign in AND complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
This event has mutliple concurrent sessions. To register, click the green button below. You will be asked to log in. You will be registered for the whole day - please complete the evaluations for only those sessions that you attend. Unattended sessions will be removed from your account, based on sign-in records, within two weeks following Seminar.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 9:00AM on Monday, October 14, 2019 will be able to request parking access on campus.
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or by clicking here », to complete your parking request. If you do not request parking on our campus, or if you do not submit your requst by the deadline, you will be re-directed upon arrival.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 9:00AM on Monday, October 14, 2019 will be able to request parking access on campus.
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or by clicking here », to complete your parking request. If you do not request parking on our campus, or if you do not submit your requst by the deadline, you will be re-directed upon arrival.
HANDOUTS
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against electronic credit reporting on this website. Sessions you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT
Participants must claim all CPE credit electronically. Participants may claim no more than one 45-minute session for each time block. To do so, participants must complete an online evaluation for those sessions attended no later than two weeks following the sessions. Participants must be logged on and registered in order to view and complete the evaluation(s). Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign in sheets, the offending participant forfeits CE credit.
Following successful completion of an evaluation, a report will be automatically submitted to CPE monitor using the date of birth and NABP e-Profile ID stored in your user profile. Please allow up to 48 hours for our systems to sync before credit becomes visible in your online NABP account. Participants are responsible for ensuring accuracy of credit reporting and receipt of credit in NABP. It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within one week of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact our office as soon as possible. To best comply with ACPE's CE credit reporting policy, St. Louis College of Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After two weeks, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close October 29, 2019 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify us in advance so that we may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Oct 15, 2019 01:00 AM - 04:00 AM
Fee
$0.00
CE Hours
8.25
Registration closes on Nov 02, 2019 12:30 AM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
Registration Closed
Registration Closed
Cerebral embolism due to atrial fibrillation is associated with up to 26% of all ischemic strokes. Previous observational studies have identified that, within the first 14 days after an atrial fibrillation-associated ischemic stroke, patients have a greater risk of recurrence of stroke, which may range from 0.5% to 1.3% per day. Within the early days after an ischemic stroke, patients are also at a greater risk of hemorrhagic transformation. Current guidelines do not provide strong, specific evidence regarding a time frame for anticoagulation reinitiation after an ischemic stroke secondary to atrial fibrillation. Due to the increased risk for stroke recurrence and early hemorrhagic transformation in the days following an acute ischemic stroke, the risks and benefits of reinitiating anticoagulation in these patients must be weighed. This presentation will assess the optimal timing of reinitiating anticoagulation after an atrial fibrillation-associated ischemic stroke based on recent literature and guideline recommendations to determine which patients would be candidates for early reinitiation versus later reinitiation.
Speaker(s)/Author(s)
|
Emily Shor, Pharm.D.
|
Activity Number
0033-0000-19-092-L01-P
Date:
10/15/19
Time:
01:00 AM - 01:45 PM
CE Hours
0.75
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
Antimicrobial stewardship and antimicrobial resistance has become increasingly important to address. Acute cystitis is a diagnosis where pharmacists can have a major impact on optimizing antimicrobial stewardship. This activity will discuss the importance of antimicrobial stewardship in acute cystitis therapy and present opportunities for pharmacists to optimize antimicrobial stewardship in acute cystitis treatment. The goal for the audience is to recognize the importance of antimicrobial stewardship and learn ways to implement antimicrobial stewardship principles in acute cystitis treatment.
Speaker(s)/Author(s)
|
Leslie Young,Pharm.D |
Activity Number
0033-0000-19-093-L01-P
Date:
10/15/19
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
With the new addition of pharmacist-prescribed nicotine replacement therapy (NRT) in Missouri, there are questions about electronic cigarettes (e-cigarettes) being used as NRT for smoking cessation. There has been some evidence suggesting e-cigarettes have potential in helping cigarette smokers quit, but there is very little known about their safety. This presentation will explore the fascination with e-cigarettes, the efficacy of e-cigarettes in regards to smoking cessation, and the current known safety concerns related to e-cigarette use in general. By the end of the presentation, attendees should be able to apply this knowledge to clinical practice to determine if e-cigarettes should be a product recommended for smoking cessation.
Speaker(s)/Author(s)
|
Kacee Verhovec,Pharm.D. |
Activity Number
0033-0000-19-095-L01-P
Date:
10/15/19
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 354
Registration Closed
Registration Closed
Registration Closed
Post-transplant lymphoproliferative disease (PTLD) is a potential common complication in immunocompromised solid organ transplant recipients (SOTR). Management of this complex and high mortality disease state often requires an interdisciplinary team with pharmacist involvement.
This presentation aims to first identify the risk factors and prevention strategies treatment teams can employ for their patients, review current literature related to the treatment of PTLD, and expand upon where novel therapies may play a role in the treatment guidelines in the future. Additionally, it will highlight the pharmacists role in helping manage immunosuppression medications for a patient at risk, or who develops or who clears PTLD.
This presentation aims to first identify the risk factors and prevention strategies treatment teams can employ for their patients, review current literature related to the treatment of PTLD, and expand upon where novel therapies may play a role in the treatment guidelines in the future. Additionally, it will highlight the pharmacists role in helping manage immunosuppression medications for a patient at risk, or who develops or who clears PTLD.
Speaker(s)/Author(s)
|
Annie Thorndyke,Pharm.D. |
Activity Number
0033-0000-19-097-L01-P
Date:
10/15/19
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 355
Registration Closed
Registration Closed
Registration Closed
The purpose of this presentation is to evaluate current literature comparing low molecular weight heparin (LMWH) versus direct oral anticoagulants (DOACs) for treatment of venous thromboembolism (VTE) in cancer patients. Throughout this presentation epidemiolgy, prognosis, pathogensis, risk factors, and guideline recommendations for VTE treatment in cancer patients wil be discussed. There will also be a review of clinically relevant trials such as the CLOT, EINSTEIN and AMPLIFY trials which led to the development of the Hokusai VTE Cancer and SELECT-D trials. The Hokusai VTE Cancer and SELECT-D trials provide evidence that edoxaban and rivaroxaban may be reasonable options for the treatment of VTE in cancer patients over LMWH in patients who are not at high risk of bleeding. Based on these two trials there has been updates to the NCCN and ASCO Guidelines to indicate were DOACs potential place in therapy are in treating VTE in cancer patients. There are three studies the Caravaggio, ADAM VTE, and CANVAS trials which may provide future input on the treatment of VTE in cancer patients. The overall goal for the audience is to discuss current literature comparing LMWH versus DOACs and then design a patient-centered medication regimen for the treatment of VTE in a cancer patient.
Speaker(s)/Author(s)
|
Kalee Huddleston,Pharm.D. |
Activity Number
0033-0000-19-100-L01-P
Date:
10/15/19
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
Increasing incidence of beta-lactam resistant pathogens in pediatric patients complicate care due to limited
Availability of safe and effective antimicrobial agents that retain activity against these pathogens. Combination beta lactams with novel non-beta-lactam beta-lactamase inhibitors have proven to be effective in restoring activity against these resistant gram negative organisms. Within the last few years the United States Food and Drug Administration has approved several new antibiotics that target carbapenem resistant gram negative organisms with expanding indications for use in pediatric populations. This seminar will explore treatment options for infections caused by carbapenem-resistant organisms in pediatric patients. The seminar is designed to describe patterns of carbapenem-resistance in gram negative organisms, review literature supporting treatment of infections caused by carbapenem-resistant gram negative organisms in pediatric patients, and summarize treatment options for targeted carbapenem resistance pattern.
Speaker(s)/Author(s)
|
Rosemary Emelue Ezinwanne,Pharm.D. |
Activity Number
0033-0000-19-103-L01-P
Date:
10/15/19
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
This CE presentation will explore treatment options besides opioids for management of hip and knee arthroplasty postoperative pain in opioid naive patients. Pertinent literature of the alternative agents will be evaluated to determine how each agent effects overall opioid requirement, pain scores, hospital length of stay, adverse events, and other relative markers. This will serve to help pharmacists understand the place in therapy of opioid alternatives for treating postoperative pain in this patient population.
Speaker(s)/Author(s)
|
Kristen Robles, Pharm.D. |
Activity Number
0033-0000-19-096-L01-P
Date:
10/15/19
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 354
Registration Closed
Registration Closed
Registration Closed
Mucormycosis is an opportunistic, invasive fungal infection most commonly diagnosed in individuals receiving treatment for hematologic malignancies or undergoing transplantation. Mucormycosis is associated with significant morbidity and mortality, with mortality rates ranging from 52-91%. Prompt diagnosis and treatment is essential in the management of mucormycosis. However, treatment of mucormycosis is difficult as there are few treatment options available and limited data from well-designed clinical trials to guide therapy. Lipid formulations of amphotericin B are considered the drug of choice for primary treatment of mucormycosis. However, long-term therapy with amphotericin B is often limited by its IV-only formulation and serious adverse effects, such as nephrotoxicity and infusion-related reactions.
Newer triazoles, including posaconazole and isavuconazole, have in vitro activity against Mucormycetes. These agents may represent promising treatment options for mucormycosis because of their favorable safety profiles and availability in both oral and IV formulations. However, evidence regarding their use in the treatment of mucormycosis, especially as primary treatment, is limited. The goal of this presentation is to compare amphotericin B-based therapy to therapy with posaconazole or isavuconazole to determine the optimal primary treatment option for mucormycosis.
.
Speaker(s)/Author(s)
|
Caroline Powers, Pharm.D. |
Activity Number
0033-0000-19-098-L01-P
Date:
10/15/19
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 355
Registration Closed
Registration Closed
Registration Closed
Previous evidence regarding use of C-reactive protein (CRP) and procalcitonin (PCT) in the management of COPD exacerbations and other conditions will be briefly reviewed, along with a review of how the most recent clinical guidelines interpret their use. New studies regarding the use of PCT and CRP will then be examined in depth, in order to explore where their use best fits in clinical practice. This discussion will include a comparison of these two inflammatory markers and how they should be examined in future studies.
Speaker(s)/Author(s)
|
Alexander Stumphauzer,Pharm.D. |
Activity Number
0033-0000-19-094-L01-P
Date:
10/15/19
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
Alcohol withdrawal syndrome is defined by the Diagnostic and Statistical Manual of Mental Disorders (DMS-5) as a life-threatening medical condition caused by the dysregulation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). The primary treatment goal for patients suffering from alcohol withdrawal syndrome is to prevent the harmful manifestations of withdrawal including alcohol withdrawal seizures and delirium tremens. Signs of symptoms of alcohol withdrawal present differently in each patient based on patient specific characteristics making the treatment of alcohol withdrawal difficult. The Clinical Institute Withdrawal Assessment Scale (CIWA-Ar) is used to help quantify the severity of a patient’s withdrawal syndrome by assessing ten common withdrawal manifestations and assigning a score based on severity. Currently, the standard-of-care for alcohol withdrawal syndrome is symptom-triggered benzodiazepines administered according to local institution protocol. In a symptom-triggered benzodiazepine protocol, benzodiazepines are administered based on the patient’s CIWA-Ar score, often causing a burden on health care resources due to the need for frequent patient assessment. Based on its pharmacokinetic properties and limited evidence, phenobarbital has been infrequently used for the treatment of alcohol withdrawal. However, with an effort to decrease the health resources used for alcohol withdrawal, health care practitioners are questioning if phenobarbital can be administered safely and effectively for the treatment of alcohol withdrawal syndrome. This seminar will review the pathophysiology of alcohol withdrawal, the current accepted treatment strategies for alcohol withdrawal, and the available evidence regarding the use of phenobarbital as an alternative to symptom-triggered benzodiazepines for the treatment of alcohol withdrawal syndrome.
Speaker(s)/Author(s)
|
Lauren Jacobsmeyer, Pharm.D.
|
Activity Number
0033-0000-19-099-L01-P
Date:
10/15/19
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 354
Registration Closed
Registration Closed
Registration Closed
This seminar will provide an overview of the management of MRSA bacteremia and commonly used antibiotics, followed by a review of the literature surrounding salvage therapy of MRSA bacteremia. Studies looking at commonly used monotherapy and combination therapy options for persistent MRSA bacteremia will be presented and evaluated, with the end goal of educating attendees on the pros, cons, and evidence behind different strategies for the management of persistent MRSA bacteremia.
Speaker(s)/Author(s)
|
Michelle Ting,Pharm.D. |
Activity Number
0033-0000-19-101-L01-P
Date:
10/15/19
Time:
02:50 PM - 03:40 PM
CE Hours
0.75
Location
ARB 355
Registration Closed
